Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Kidney stones: an update on current pharmacological management and future directions.

Xu H, Zisman AL, Coe FL, Worcester EM.

Expert Opin Pharmacother. 2013 Mar;14(4):435-47. doi: 10.1517/14656566.2013.775250. Review.

2.

Evaluation and medical management of kidney stones in children.

Tasian GE, Copelovitch L.

J Urol. 2014 Nov;192(5):1329-36. doi: 10.1016/j.juro.2014.04.108. Epub 2014 Jun 21. Review.

PMID:
24960469
3.
4.

Metabolic abnormalities associated with calyceal diverticular stones.

Auge BK, Maloney ME, Mathias BJ, Pietrow PK, Preminger GM.

BJU Int. 2006 May;97(5):1053-6.

5.

Pharmacotherapy of kidney stones.

Pak CY.

Expert Opin Pharmacother. 2008 Jun;9(9):1509-18. doi: 10.1517/14656566.9.9.1509 . Review.

PMID:
18518781
6.

Optimum nutrition for kidney stone disease.

Heilberg IP, Goldfarb DS.

Adv Chronic Kidney Dis. 2013 Mar;20(2):165-74. doi: 10.1053/j.ackd.2012.12.001. Review.

PMID:
23439376
7.

[Randomized trials in the prevention of recurrent calcium oxalate stones].

Presne C, Monge M, Bataille P, el Esper N, Choukroun G, Fournier A.

Nephrologie. 2003;24(6):303-7. Review. French.

PMID:
14584297
8.

Treatment and prevention of kidney stones: an update.

Frassetto L, Kohlstadt I.

Am Fam Physician. 2011 Dec 1;84(11):1234-42. Review.

9.

Medical management of stone disease.

Delvecchio FC, Preminger GM.

Curr Opin Urol. 2003 May;13(3):229-33. Review.

PMID:
12692447
10.

The role of calcium in the prevention of kidney stones.

Heller HJ.

J Am Coll Nutr. 1999 Oct;18(5 Suppl):373S-378S. Review.

PMID:
10511317
11.

Diet and renal stone formation.

Trinchieri A.

Minerva Med. 2013 Feb;104(1):41-54.

PMID:
23392537
12.

Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment.

Caudarella R, Vescini F.

Arch Ital Urol Androl. 2009 Sep;81(3):182-7. Review.

PMID:
19911682
13.

Recurrent Nephrolithiasis in Adults: Comparative Effectiveness of Preventive Medical Strategies [Internet].

Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Monga M.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jul.

14.

Prevention of recurrent nephrolithiasis.

Goldfarb DS, Coe FL.

Am Fam Physician. 1999 Nov 15;60(8):2269-76. Review.

15.

Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions.

Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD.

J Urol. 2003 Feb;169(2):465-9.

PMID:
12544288
16.

Use of drugs for nephrolithiasis.

Marangella M, Vitale C, Bagnis C, Petrarulo M, Tricerri A.

Clin Cases Miner Bone Metab. 2008 May;5(2):131-4.

17.

Pharmacological interventions for preventing complications in idiopathic hypercalciuria.

Escribano J, Balaguer A, Pagone F, Feliu A, Roqué I Figuls M.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004754. doi: 10.1002/14651858.CD004754.pub2. Review.

PMID:
19160242
18.

Developments in stone prevention.

Straub M, Hautmann RE.

Curr Opin Urol. 2005 Mar;15(2):119-26. Review.

PMID:
15725936
19.

The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.

Siener R, Schade N, Nicolay C, von Unruh GE, Hesse A.

J Urol. 2005 May;173(5):1601-5.

PMID:
15821507
20.

Renal stone disease: Causes, evaluation and medical treatment.

Heilberg IP, Schor N.

Arq Bras Endocrinol Metabol. 2006 Aug;50(4):823-31. Review.

Items per page

Supplemental Content

Write to the Help Desk